Rare
lephants
Screener
Toggle theme
CRISPR THERAPEUTICS AG
CRSP
·
Healthcare, Drug Manufacturers - General
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2021
FY2019
FY2015
Total Cash from Operations:
$789.9M
Line Item
Value
% of Total
Capital Expenditures
$81.7M
10.3%
Other Investing
$708.2M
89.7%
Net Cash Flow
$0
0.0%
Download CSV
